Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Serial MRI and CSF biomarkers in normal aging, MCI, and AD.

Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2010 Jul 13;75(2):143-51. doi: 10.1212/WNL.0b013e3181e7ca82.

2.

Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study.

Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, Nordberg A, Larsson A, Lannfelt L, Basun H, Kilander L.

Dement Geriatr Cogn Disord. 2010;29(3):204-12. doi: 10.1159/000281832. Epub 2010 Mar 20.

PMID:
20332638
3.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M.

Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.

PMID:
20189881
4.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.

5.

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.

Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM.

EMBO Mol Med. 2009 Nov;1(8-9):371-80. doi: 10.1002/emmm.200900048.

6.

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW.

Neurology. 2010 Jan 19;74(3):201-9. doi: 10.1212/WNL.0b013e3181cb3e25. Epub 2009 Dec 30.

7.

Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC.

Arch Neurol. 2009 Dec;66(12):1557-62. doi: 10.1001/archneurol.2009.279.

8.

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.

Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA.

Arch Neurol. 2009 Dec;66(12):1469-75. doi: 10.1001/archneurol.2009.269.

9.

Relationships between biomarkers in aging and dementia.

Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2009 Oct 13;73(15):1193-9. doi: 10.1212/WNL.0b013e3181bc010c.

10.

Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.

Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, Viitanen M, Någren K, Helin S, Scheinin M, Rinne JO.

Neurology. 2009 Oct 13;73(15):1186-92. doi: 10.1212/WNL.0b013e3181bacf1b. Epub 2009 Sep 2.

PMID:
19726751
11.

Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.

Tolboom N, van der Flier WM, Yaqub M, Boellaard R, Verwey NA, Blankenstein MA, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN.

J Nucl Med. 2009 Sep;50(9):1464-70. doi: 10.2967/jnumed.109.064360. Epub 2009 Aug 18.

12.

Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.

Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O.

PLoS One. 2009 Jul 17;4(7):e6294. doi: 10.1371/journal.pone.0006294.

13.

In vivo mapping of amyloid toxicity in Alzheimer disease.

Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Någren K, Rinne JO.

Neurology. 2009 Apr 28;72(17):1504-11. doi: 10.1212/WNL.0b013e3181a2e896.

PMID:
19398705
14.

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2009 May;132(Pt 5):1355-65. doi: 10.1093/brain/awp062. Epub 2009 Mar 31.

15.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.

16.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
17.

Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.

Grimmer T, Riemenschneider M, Förstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A.

Biol Psychiatry. 2009 Jun 1;65(11):927-34. doi: 10.1016/j.biopsych.2009.01.027. Epub 2009 Mar 6.

18.

Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM.

Ann Neurol. 2009 Feb;65(2):176-83. doi: 10.1002/ana.21559.

19.

Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2009 May;132(Pt 5):1310-23. doi: 10.1093/brain/awn320. Epub 2008 Nov 28.

20.

Frequent amyloid deposition without significant cognitive impairment among the elderly.

Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE.

Arch Neurol. 2008 Nov;65(11):1509-17. doi: 10.1001/archneur.65.11.1509.

Items per page

Supplemental Content

Write to the Help Desk